Evidence map›Paper›PMID 31275464›Full record

ArticleAnnals of vascular diseases2019

Molecular Pharmacological Approaches for Treating Abdominal Aortic Aneurysm.

Takashi Miyake, Tetsuo Miyake, Tomohiro Kurashiki, Ryuichi Morishita

Open access · goldAbstract read
In one paragraph

Article in Annals of vascular diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Review
  6. Role of Extracellular Matrix and Inflammation in Abdominal Aortic Aneurysm.International journal of molecular sciences · 2022
    Review
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Takashi MiyakeDepartment of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Tetsuo MiyakeDepartment of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Tomohiro KurashikiDepartment of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Ryuichi MorishitaDepartment of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, Suita, Osaka, Japan.
Osaka University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Abdominal aortic aneurysm (AAA) is considered to be a potent life-threatening disorder in elderly individuals. Although many patients with a small AAA are detected during routine abdominal screening, there is no effective therapeutic option to prevent the progression or regression of AAA in the clinical setting. Recent advances in molecular biology have led to the identification of several important molecules, including microRNA and transcription factor, in the process of AAA formation. Regulation of these factors using nucleic acid drugs is expected to be a novel therapeutic option for AAA. Nucleic acid drugs can bind to target factors, mRNA, microRNA, and transcription factors in a sequence-specific fashion, resulting in a loss of function of the target molecule at the transcriptional or posttranscriptional level. Of note, inhibition of a transcription factor using a decoy strategy effectively suppresses experimental AAA formation, by regulating the expression of several genes associated with the disease progression. This review focuses on recent advances in molecular therapy of using nucleic acid drugs to treat AAA.

Indexed as

abdominal aortic aneurysmdecoy oligodeoxynucleotidenucleic acid drugtranscription factor

Identifiers

PMID31275464
PMCPMC6600097
OpenAlexW2936164648

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.